Top Markets
#1 Pons Pons +54.09%
#2 Smilek to the Bank Smilek to the Bank +50.56%
#3 Purr Purr +49.34%
#4 Kinetiq Kinetiq +27.31%
#5 Non-Playable Coin Non-Playable Coin +26.21%
#6 ApeX ApeX +25.57%
#7 Pudgy Penguins Pudgy Penguins +21.07%
#8 OriginTrail OriginTrail +20.36%
#9 Morpho Morpho +20.09%
#10 Grass Grass +19.96%
Coin of the day
Pons Pons
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Talaris Therapeutics, Inc. Talaris Therapeutics, Inc.

Talaris Therapeutics, Inc.

TALS
Classement en actions #21258
Talaris Therapeutics, Inc. is a cell therapy company operating in the United... Talaris Therapeutics, Inc. is a cell therapy company operating in the United States, currently in its late clinical development stages. Its mission involves pioneering an allogeneic hematopoietic stem cell transplantation strategy designed to revolutionize treatment paradigms for solid organ transplantation, severe autoimmune conditions, and significant non-malignant blood, immune, and metabolic disorders. The company's flagship product, FCR001, is an innovative allogeneic cell therapy presently in Phase II clinical trials for patients undergoing living donor kidney transplantation. Beyond this, Talaris Therapeutics is actively advancing FCR002 for use in deceased donor kidney transplants, investigating FCR001 for individuals with a severe form of scleroderma, and exploring its applicability for a range of other serious non-malignant blood, immune, or metabolic conditions. Founded in 1988, the company maintains its headquarters in Louisville, Kentucky.
Prix de l'action
$2.72
Dernière synchronisation: 2023-10-19
Capitalisation boursière
$111.47M
Changement (1 jour)
-0.73%
Changement (1 an)
0.00%
Pays
US
Échange Talaris Therapeutics, Inc. (TALS)

Catégorie

Healthcare
Revenus pour Talaris Therapeutics, Inc. (TALS)
Revenus en Aug 2026 TTM : 0
Selon les derniers rapports financiers de Talaris Therapeutics, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Talaris Therapeutics, Inc. de 2026 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
Pas assez de données pour les dates fournies.
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH